Data Generated to Date Support Potential for Aclaris’ ATI-2138 to Impact Several Human Inflammatory Diseases - WAYNE, Pa., ...

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal ...

SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the 'Company') declared today that it is ready to fight the bird f ...

Results from a new study published in Clinical and Translational Immunology found that dual-target antibody therapy can enhance cancer-fighting T cells more effectively than current single-target ...

FIBRONEER™-ILD was a double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of nerandomilast ...

The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or ...